Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

60275 1492790397HCLSReviewGreeceApril2017.pdf
Energy Boardroom

Analyst: GlaxoSmithKline's Tykerb dead in the water after breast cancer failure

17.06.2014 / Fierce Pharma

GlaxoSmithKline's cancer treatment Tykerb took a blow last month when it failed a major late-stage trial in breast cancer. Now, at least one analyst figures the drug is crippled by that data–and that marketing it for breast cancer would be a waste of money.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: